CpG oligodeoxynucleotides augment the murine immune response to theYersinia pestisF1-V vaccine in bubonic and pneumonic models of plague

The current U.S. Department of Defense candidate plague vaccine is a fusion between twoYersinia pestisproteins: the F1 capsular protein, and the low calcium response (Lcr) V-protein. We hypothesized that an immunomodulator, such as CpG oligodeoxynucleotide (ODN)s, could augment the immune response t...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2009-04, Vol.27 (16), p.2220
Main Authors: Amemiya, Kei, Meyers, Jennifer L, Rogers, Taralyn E, Fast, Randy L, Bassett, Anthony D, Worsham, Patricia L, Powell, Bradford S, Norris, Sarah L, Krieg, Arthur M, Adamovicz, Jeffrey J
Format: Article
Language:English
Subjects:
Antigens
Immune system
Medical research
Vaccines
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The current U.S. Department of Defense candidate plague vaccine is a fusion between twoYersinia pestisproteins: the F1 capsular protein, and the low calcium response (Lcr) V-protein. We hypothesized that an immunomodulator, such as CpG oligodeoxynucleotide (ODN)s, could augment the immune response to the plague F1-V vaccine in a mouse model for plague. CpG ODNs significantly augmented the antibody response and efficacy of a single dose of the plague vaccine in murine bubonic and pneumonic models of plague. In the latter study, we also found an overall significant augmentation the immune response to the individual subunits of the plague vaccine by CpG ODN 2006. In a long-term, prime-boost study, CpG ODN induced a significant early augmentation of the IgG response to the vaccine. The presence of CpG ODN induced a significant increase in the IgG2a subclass response to the vaccine up to 5 months after the boost. Our studies showed that CpG ODNs significantly augmented the IgG antibody response to the plague vaccine, which increased the probability of survival in murine models of plague (P
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2009.02.016